Cancer is a major medical problem worldwide. Due to its high heterogeneity, the use of the
same drugs or surgical methods in patients with the same tumor may have different curative …

Mass-spectrometry-based proteomics is continuing to make major contributions to the
discovery of fundamental biological processes and, more recently, has also developed into …

Small molecule splicing modifiers have been previously described that target the general
splicing machinery and thus have low specificity for individual genes. Several potent …

The NCI-60 cell line collection is a very widely used panel for the study of cellular
mechanisms of cancer in general and in vitro drug action in particular. It is a model system …

Nowadays, proteomic studies no longer focus only on identifying as many proteins as
possible in a given sample, but aiming for an accurate quantification of them. Especially in …

Inhibition of the DNA damage checkpoint kinase WEE1 potentiates genotoxic
chemotherapies by abrogating cell-cycle arrest and proper DNA repair. However, WEE1 is …

Preclinical stages in the drug discovery process require a multitude of biochemical and
genetic assays in order to characterize the effects of drug candidates on cellular systems …

Hematologic malignancies represent the fourth most frequently diagnosed cancer in
economically developed countries. In hematologic malignancies normal hematopoiesis is …

Advances in phosphopeptide enrichment methods enable the identification of thousands of
phosphopeptides from complex samples. Current offline enrichment approaches using TiO …

Proteins that are important indicators of physiological or pathological states, can provide
information for the identification of early and differential markers for disease. Saliva, contains …